ERBB2 and breast carcinoma: In this study, we first analyzed the expression of miR-139-5p in different molecular subtypes of breast cancer and found that miR-139-5p was lowly expressed in luminal A, luminal B, HER2-enriched, and basal-like breast cancers, and the expression was significantly different in different molecular subtypes.